Literature DB >> 7966068

Lipid profiles in patients with systemic lupus erythematosus.

K H Leong1, E T Koh, P H Feng, M L Boey.   

Abstract

OBJECTIVE: To determine the prevalence of abnormal lipid profiles in 100 consecutive patients with systemic lupus erythematosus (SLE) and the role of potential risk factors.
METHODS: Fasting lipid profiles were measured using an enzymatic method. Biodata noted for each patient included age, sex, race, presence of diabetes mellitus, thyroid disease, familial hyperlipidemia, smoking history, presence of nephritis or nephrotic syndrome, lupus activity as measured by the lupus activity criteria count (LACC), duration of SLE, use of antihypertensive agents and the current and cumulative dose of steroids. Statistical analysis was done using PC SAS software.
RESULTS: Seventy-three patients had abnormal lipid profiles. Patients with normal and abnormal profiles were comparable in age, sex, race, history of diabetes mellitus, familial hyperlipidemia, and smoking. Abnormal values of total cholesterol (TC), low density lipoprotein (LDL), triglycerides (TG) and TC/high density lipoprotein (HDL) were associated with renal involvement and high dose corticosteroids (> 30 mg prednisolone/day). HDL levels were significantly lower in patients receiving high dose corticosteroids (p < 0.05). In patients with active lupus disease but without renal disease, lipid abnormalities were not observed.
CONCLUSION: Abnormal lipid profiles are common in this group of patients with SLE. High dose steroids and the nephrotic syndrome are important contributing factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7966068

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  20 in total

Review 1.  Recognition and management of systemic lupus erythematosus.

Authors:  J O Schroeder; H H Euler
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 2.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

3.  Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies.

Authors:  Sara Kashef; Mohammad Mehdi Ghaedian; Akbar Rajaee; Abbas Ghaderi
Journal:  Rheumatol Int       Date:  2006-08-30       Impact factor: 2.631

4.  [Cardiovascular monitoring of patients with systemic lupus erythematosus].

Authors:  H Schotte; H Becker; W Domschke; M Gaubitz
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

Review 5.  Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Authors:  Shipra Agrawal; Joshua J Zaritsky; Alessia Fornoni; William E Smoyer
Journal:  Nat Rev Nephrol       Date:  2017-11-27       Impact factor: 28.314

6.  Sequential evaluation of clinical and laboratory changes amongst children suffering from lupus nephritis during intermittent intravenous cyclophosphamide therapy.

Authors:  Shih-Jung Chiu; Liang-Shiou Ou; Tien-Lung Tsai; Iou-Jih Hung; Jing-Long Huang
Journal:  Clin Rheumatol       Date:  2005-11-10       Impact factor: 2.980

7.  Risk factors for coronary heart disease in connective tissue diseases.

Authors:  Awal Al Husain; Ian N Bruce
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-06       Impact factor: 5.346

8.  Food restriction and fish oil suppress atherogenic risk factors in lupus-prone (NZB x NZW) F1 mice.

Authors:  Alagarraju Muthukumar; Khaliquz Zaman; Richard Lawrence; Jeffery L Barnes; Gabriel Fernandes
Journal:  J Clin Immunol       Date:  2003-01       Impact factor: 8.317

Review 9.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

10.  Contemporary treatment of systemic lupus erythematosus: an update for clinicians.

Authors:  Maame B Amissah-Arthur; Caroline Gordon
Journal:  Ther Adv Chronic Dis       Date:  2010-07       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.